Differential Antidepressant Symptom Efficacy: Placebo-Controlled Comparisons of Duloxetine and SSRIs (Fluoxetine, Paroxetine, Escitalopram)
Authors:
- Craig H. MallinckrodtCMCraig H. Mallinckrodt
- Apurva PrakashAPApurva Prakash
- John P. HoustonJHJohn P. Houston
- Ralph SwindleRSRalph Swindle
- Michael J. DetkeMDMichael J. Detke
- Maurizio FavaMFMaurizio Fava
- 23 November 2007
- journal article
- clinical trial
- Published by S. Karger AG in Neuropsychobiology
- Vol. 56 (2-3) , 73-85
Abstract
Objective: To test the hypothesis that in patients with major depressive disorder (MDD), the response for specific Hamilton Depression Rating Scale items will differ for duloxetine compared with selective serotonin reuptake inhibitors (SSRIs) and that patterns of response will differ based on symptom severity at baseline. Method: Data were pooled from all Lilly-sponsored clinical trials where duloxetine was compared with placebo and an SSRI in patients with MDD: 7 randomized, double-blind, fixed-dose, 8-week studies of duloxetine (n = 1,133) versus SSRI (n = 689) versus placebo (n = 641). Duloxetine doses were 40, 60, 80 and 120 mg/day. SSRI doses were 10 mg/day (escitalopram) and 20 mg/day (fluoxetine and paroxetine). Results: Compared to SSRI-treated patients, duloxetine-treated patients had a significantly greater (p ≤ 0.05) reduction in the 17-item Hamilton Depression Rating Scale (HAMD17) total score and HAMD17 items of work and activities, psychomotor retardation, genital symptoms and hypochondriasis. Differences favoring the SSRIs approached significance for middle insomnia (p = 0.057) and late insomnia (p = 0.06), with effect sizes at least twice the magnitude of the corresponding effect sizes for duloxetine. Similarly, the advantage for duloxetine versus the SSRIs approached significance for general somatic symptoms (p = 0.056), with an effect size twice that observed for the SSRIs. The HAMD17 total score difference was driven mostly by patients with lower baseline MDD severity (HAMD17 total score ≤19), where the HAMD17 effect size advantage for duloxetine over combined SSRIs was statistically significant (p = 0.031). Conclusion: Potentially important differences in symptom response patterns were found between duloxetine and the combined SSRIs depending on symptom severity, and different HAMD17 items responded differently to duloxetine compared with SSRIs. Understanding these differences may be useful in tailoring antidepressant therapy for individual patients.Keywords
This publication has 36 references indexed in Scilit:
- Changes in Sexual Functioning Associated with Duloxetine, Escitalopram, and Placebo in the Treatment of Patients with Major Depressive DisorderThe Journal of Sexual Medicine, 2007
- Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority studyCurrent Medical Research and Opinion, 2007
- The Montgomery Äsberg and the Hamilton ratings of depression: A comparison of measuresEuropean Neuropsychopharmacology, 2006
- Current Status of Augmentation and Combination Treatments for Major Depressive Disorder: A Literature Review and a Proposal for a Novel Approach to Improve PracticePsychotherapy and Psychosomatics, 2006
- Comparing the Effects of Antidepressants: Consensus Guidelines for Evaluating Quantitative Reviews of Antidepressant EfficacyNeuropsychopharmacology, 2005
- Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trialEuropean Neuropsychopharmacology, 2004
- Duloxetine in the Treatment of DepressionJournal of Clinical Psychopharmacology, 2004
- Fluvoxamine as effective as clomipramine against symptoms of severe depression: results from a multicentre, double‐blind studyHuman Psychopharmacology: Clinical and Experimental, 2003
- Duloxetine in the Treatment of Major Depressive DisorderThe Journal of Clinical Psychiatry, 2002
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960